Skandinaviska Enskilda Banken Ab (Publ) Immunity Bio, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $21.6 Billion
- Q4 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 295,950 shares of IBRX stock, worth $905,607. This represents 0.0% of its overall portfolio holdings.
Number of Shares
295,950
Previous 270,950
9.23%
Holding current value
$905,607
Previous $1.01 Million
24.68%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding IBRX
# of Institutions
229Shares Held
82.3MCall Options Held
1.02MPut Options Held
2.25M-
Vanguard Group Inc Valley Forge, PA17.3MShares$53 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$35 Million0.0% of portfolio
-
State Street Corp Boston, MA9.79MShares$29.9 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.01MShares$12.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.84MShares$11.8 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $1.22B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...